MedicineNews.net - Medical Updates

Apixaban associated with lower risk of stroke and lower rates of major bleeding compared to Warfarin

The findings from a real-world data analysis of the U.S. Humana database, in which treatment with Apixaban ( Eliquis ) was associated with a significantly lower risk of stroke / systemic embolism and ... read article

Positive results from PROSPER trial of Enzalutamide in patients with non-metastatic castration-resistant prostate cancer

The phase 3 PROSPER trial evaluating Enzalutamide ( Xtandi ) plus androgen deprivation therapy ( ADT ) versus ADT alone in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CR ... read article

The combination of Sacubitril and Valsartan protects against cardiac rupture and improves survival after acute myocardial infarction in murine model

A study examined the effects of LCZ696 ( Sacubitril and Valsartan; Entresto ) on acute experimental myocardial infarction ( MI ) in mice and whether it has cardioprotective effects beyond renin-angiot ... read article

Nivolumab in glioblastoma multiforme, CheckMate -143 did not meet its primary endpoint of improved overall survival

CheckMate -143, a randomized phase 3 clinical trial evaluating the efficacy and safety of Nivolumab ( Opdivo ) in patients with first recurrence of glioblastoma multiforme ( GBM ), did not meet its pr ... read article

Androgen receptor-inhibitors: Enzalutamide improves metastasis-free survival in patients with non-metastatic castration-resistant prostate cancer

The phase 3 PROSPER trial evaluating Enzalutamide ( Xtandi ) plus androgen deprivation therapy ( ADT ) versus ADT alone in patients with non-metastatic ( M0 ) castration-resistant prostate cancer ( CR ... read article

Parkinson's disease: Safinamide improves motor function, overall clinical status and health-related quality of life

Safinamide ( Xadago ) is an orally active, selective, reversible monoamine oxidase-B inhibitor with both dopaminergic and non-dopaminergic ( glutamatergic ) properties. In the European Union, Safi ... read article

Nivolumab in glioblastoma multiforme, CheckMate -143 did not meet its primary endpoint of improved overall survival

CheckMate -143, a randomized phase 3 clinical trial evaluating the efficacy and safety of Nivolumab ( Opdivo ) in patients with first recurrence of glioblastoma multiforme ( GBM ), did not meet its pr ... read article

Advanced BRCA-related breast cancer: Olaparib, a PARP inhibitor, is superior to chemotherapy

During the American Society of Clinical Oncology ( ASCO ) Annual Meeting, the results of the phase III OlympiAD trial demonstrating for the first time that Olaparib ( Lynparza ) is superior to chemoth ... read article

Relapsing multiple sclerosis: oral Ozanimod has shown improvements compared to Interferon beta-1a for the primary endpoint of annualized relapse rate

SUNBEAM trial, evaluating the efficacy and safety of O)zanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis ( RMS ), met the primar ... read article

Actemra is the first FDA-approved treatment for adults with giant cell arteritis

The U.S. Food and Drug Administration ( FDA ) has approved Actemra [ European Union: RoActemra ] ( Tocilizumab ) subcutaneous injection for the treatment of giant cell arteritis ( GCA ), a chronic and ... read article

uniQure will not seek marketing authorization renewal for Glybera in European Union

uniQure has announced that it will not pursue the renewal of the Glybera ( Alipogene tiparvovec ) marketing authorization in Europe when it is scheduled to expire on October 25, 2017. According to ... read article

Lung cancer: patients with responsive to Nivolumab, an immunotherapic drug, beat standard odds of survival

More than seven years after the start of one of the first clinical trials of the immunotherapy drug Nivolumab ( Opdivo ), researchers at the Johns Hopkins Kimmel Cancer Center have reported that the f ... read article

Regimen of Glecaprevir/Pibrentasvir for the treatment of chronic hepatitis C GT1-6: FDA has granted priority review

The FDA ( U.S. Food and Drug Administration ) has accepted New Drug Application ( NDA ) and granted priority review for the investigational, pan-genotypic regimen of Glecaprevir and Pibrentasvir ( G/P ... read article

Chronic hepatitis C therapy: European Medicines Agency has granted accelerated assessment to Sofosbuvir, Velpatasvir, Voxilaprevir

Gilead Sciences has announced that the Marketing Authorization Application ( MAA ) for the investigational, once-daily, single tablet regimen of Sofosbuvir 400 mg, Velpatasvir 100 mg and Voxilaprevir ... read article

Oral Ozanimod, compared to Interferon beta-1a, reduces annualized relapse rate in patients with relapsing multiple sclerosis

The phase III SUNBEAM trial, evaluating the efficacy and safety of Ozanimod, an investigational oral, selective S1P 1 and 5 receptor modulator, in patients with relapsing multiple sclerosis ( RMS ), m ... read article